Physician profile
Eric E Ehrenberg
NPI 1386679934
$9,931.60
in general payments reported to CMS, 2019-2025
40 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $250 · 2021: $813 · 2022: $1,740 · 2023: $1,687 · 2024: $2,181 · 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,739 · Education: $81.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,739.42 |
| Education | $81.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,425.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,283.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,201.44 | 2019-2025 | |
| Amgen INC. | $966.28 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $817.35 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $782.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $693.43 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $435.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $254.80 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $224.43 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.60 | 2022-2025 | |
| Astellas Pharma US INC | $155.21 | 2022-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.91 | 2019-2024 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $125.30 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $117.64 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ehrenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.